Yes, Madam Chair, I'd be happy to do that.
This was just additional guidance. It's not actually changes to the legislation, but guidance on how we will apply the legislation. That came out a number of weeks ago.
The specific concern is just to make sure that market participants, the investment bar, the people who advise firms, are put on notice that we'll be watching for concerns about what I would maybe call “predatory behaviour”. We're aware, for example, that there are firms that have depressed valuations because of the crisis and we wouldn't want to have very important Canadian companies necessarily be taken out because they happen to be in a weak position or there happens to be a vulnerability related to the crisis.
Just to note, we also have particular concerns on all of the issues around the supply chain for medical goods, services and products. We have particularly pointed concerns with regard to certain strategic assets, if you like, in the health sector. We want to make sure there as well that the market takes note that it's an area we'll be looking at a little more closely. I would say there's a particular focus on state enterprises and non-commercial actors who might be engaged in those kinds of purchases. If it's a private transaction and it's driven by the market and it's the sort of thing we would have seen before the crisis, we may be less concerned, but if it's a strategic acquisition perhaps for non-economic reasons, that's something that would be more worrying.
I would simply note that other jurisdictions have done something similar. The honourable member may be aware that Australia put out guidance that is very similar to what we have done. So a number of our peer countries have taken similar steps.